PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world Evidence

PSA Response as a Prognostic Factor of Overall Survival in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Real-world Evidence

Summary

PSA 90 response at 3 and 6 months is a strong prognostic marker for overall survival and radiographic progression-free survival in patients with metastatic horm...

Description

PSA 90 response at 3 and 6 months is a strong prognostic marker for overall survival and radiographic progression-free survival in patients with metastatic horm...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage